Pricing Evaluations
Apex provides the following services:
- Overview of pricing and reimbursement systems for the hospital sector in each of the 5 EU (France, Germany, Italy, Spain and UK) and more recently outside of the core 5 EU countries
- Information on the process of how the price for a hospital product is obtained in each country
- How reimbursement is gained (if not directly linked to drug approval)
- Identification of possible reimbursement issues or barriers in Europe that could impact on obtaining a premium price for client products
- Overview of potential issues associated with gaining formulary acceptance within the hospital sector in each country
Recent Examples include
Determining the appropriate EU pricing level for a novel oncology agent by identifying and benchmarking prices for a range of comparable products (recently launched oncology drugs, current treatments for the same target indication and other oncology agents with similar clinical benefits). The benchmark compounds were then validated by conducting research with senior hospital pharmacists and clinical trialists to gauge the relative clinical value of the novel agent versus these other agents.
Carried out pricing analysis and understanding of the drug purchasing and reimbursement process for niche EU countries. Apex conducted research on a novel anti-infective agent by a combination of focus groups and in-depth telephone interviews again with clinicians and pharmacists.
We determined the opportunity for premium pricing for a novel cardiology product in Europe by conducting research with clinicians and pharmacists. The analysis included a pharmacoeconomic assessment and identification of any potential reimbursement issues.